Trial intelligence / Profile preview

TAD: Aspirin Dose Comparison in Stable Coronary Disease

NCT00272337Phase 4Completed

Sponsor
Florida Atlantic University
Start
Oct 2006
Primary completion
Jun 2009
Modality
Orthosteric Ligands
Countries
1
01

Overview

Phase 4, randomised, double-blind trial of aspirin in coronary artery disease (CAD) (5 arms), sponsored by Florida Atlantic University. Primary endpoint: Change in Nitric Oxide Formation From Baseline at 3 months. Started Oct 2006; status: completed.

02

Drugs

aspirin
03

Conditions

coronary artery disease (CAD)

Beyond the preview

Go deeper on NCT00272337.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00272337.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call